CYTOKINETICS INC (CYTK) stock: key figures, P/E, revenue and dividend

CYTOKINETICS INC financials

About CYTOKINETICS INC

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

More stocks

• Toppan Printing Ltd (TOPPY)
• CareTrust REIT, Inc. (CTRE)
• Caris Life Sciences, Inc. (CAI)
• Financiere de Tubize SA (TUB.BR)
• InPost SA (INPST.AS)
• Shenzhen Fastprint Circuit Tech Co Ltd (002436.SZ)
• 360 Security Technology Inc (601360.SS)
• ITEQ Corp (6213.TW)
• CIG ShangHai Co Ltd Class A (603083.SS)
• Porsche Automobil Holding (PAH3.DE)
• Corteva (CTVA)
• VALMONT INDUSTRIES INC (VMI)